Pacific Biosciences of California (PACB)
$1.32
$-0.03
(-2.22%)
As on 08-Sep-2026 16:25EDT
Market cap
$420 Mln
Revenue (TTM)
$159 Mln
P/E Ratio
--
P/B Ratio
170.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-9.3 %
-
ROCE
-- %
-
Industry P/E
46.09
-
EV/EBITDA
140.8
-
Debt to Equity
-19.4
-
Book Value
$--
-
EPS
$-0.4
-
Face value
--
-
Shares outstanding
310,830,759
10 Years Aggregate
CFO
$-1,000.98 Mln
EBITDA
$-1,322.38 Mln
Net Profit
$-1,200.29 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pacific Biosciences of California (PACB)
| -29.4 | 10.9 | -9.0 | 3.9 | -50.5 | -46.6 | -17.3 |
|
BSE Sensex*
| -11.7 | -4.8 | 1.7 | -7.5 | 3.9 | 5.1 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Pacific Biosciences of California (PACB)
| 2.2 | -81.1 | 19.9 | -60.0 | -21.1 | 404.7 | -30.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pacific Biosciences of California (PACB)
|
1.3 | 419.6 | 159.3 | -131.4 | -79.6 | -- | -- | 170.7 |
| 65.6 | 8,162.7 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.0 | |
| 15.3 | 10,125.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.8 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.4 | |
| 58.4 | 8,913.0 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 185.0 | 10,637.8 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 15.3 | |
| 100.4 | 6,590.6 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.2 | 5.0 | |
| 87.4 | 5,350.1 | 1,579.2 | 145.6 | 14.3 | 8.9 | 36.9 | 3.2 | |
| 319.3 | 12,649.5 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.3 | 8.3 | |
| 168.5 | 9,458.6 | 785.1 | 41.5 | 9.9 | 2 | 232.8 | 4.6 |
Shareholding Pattern
View DetailsAbout Pacific Biosciences of California (PACB)
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT)... technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Read more
-
President, CEO & Director
Mr. Christian O. Henry M.B.A.
-
President, CEO & Director
Mr. Christian O. Henry M.B.A.
-
Headquarters
Menlo Park, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pacific Biosciences of California (PACB)
What is the current share price of Pacific Biosciences of California (PACB) Today?
The share price of Pacific Biosciences of California (PACB) is $1.32 (NASDAQ) as of 08-Sep-2026 16:25 EDT. Pacific Biosciences of California (PACB) has given a return of -50.46% in the last 3 years.
What is the current PB & PE ratio of Pacific Biosciences of California (PACB)?
Since, TTM earnings of Pacific Biosciences of California (PACB) is negative, P/E ratio is not available.
The P/B ratio of Pacific Biosciences of California (PACB) is 170.66 times as on 04-Sep-2026, a 4415 premium to its peers’ median range of 3.78 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.03 |
105.55 |
2024 |
-1.81 |
1.11 |
2023 |
-8.54 |
3.74 |
2022 |
-5.89 |
3.29 |
2021 |
-24.92 |
5.71 |
What is the 52 Week High and Low of Pacific Biosciences of California (PACB)?
The 52-week high and low of Pacific Biosciences of California (PACB) are Rs 2.73 and Rs 1.07 as of 09-Sep-2026.
What is the market cap of Pacific Biosciences of California (PACB)?
Pacific Biosciences of California (PACB) has a market capitalisation of $ 420 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pacific Biosciences of California (PACB)?
Before investing in Pacific Biosciences of California (PACB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.